NCT06114329View on ClinicalTrials.gov

Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2026

Conditions
Fabry Disease
Interventions
DRUG

AL01211

AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.

Trial Locations (6)

100034

RECRUITING

Peking University First Hospital, Beijing

200025

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai

410008

RECRUITING

Xiangya Hospital of Central South University, Changsha

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510062

RECRUITING

The First Affiliated Hospital of Sun Yat sen University, Guangzhou

610044

RECRUITING

West China Hospital, Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

AceLink Therapeutics, Inc.

INDUSTRY

NCT06114329 - Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease | Biotech Hunter | Biotech Hunter